| Year |
Citation |
Score |
| 2024 |
Wang H, Gong L, Huang X, White SD, Chung HT, Vesprini D, Petchiny TN, Fokas E, He H, Kerbel RS, Liu SK. Potentiating Salvage Radiotherapy in Radiorecurrent Prostate Cancer Through Anti-CTLA4 Therapy: Implications from a Syngeneic Model. Cancers. 16. PMID 39199612 DOI: 10.3390/cancers16162839 |
0.311 |
|
| 2022 |
Liu X, Chipurupalli S, Jiang P, Tavasoli M, Yoo BH, McPhee M, Mazinani S, Francia G, Kerbel RS, Rosen KV. ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth. Cell Death & Disease. 13: 687. PMID 35933456 DOI: 10.1038/s41419-022-05117-9 |
0.333 |
|
| 2022 |
Huijbers EJM, Khan KA, Kerbel RS, Griffioen AW. Tumors resurrect an embryonic vascular program to escape immunity. Science Immunology. 7: eabm6388. PMID 35030032 DOI: 10.1126/sciimmunol.abm6388 |
0.324 |
|
| 2021 |
Khan KA, Wu FT, Cruz-Munoz W, Kerbel RS. Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. Embo Molecular Medicine. e08253. PMID 34125494 DOI: 10.15252/emmm.201708253 |
0.358 |
|
| 2020 |
Khan KA, Ponce de Léon JL, Benguigui M, Xu P, Chow A, Cruz-Muñoz W, Man S, Shaked Y, Kerbel RS. Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer. Npj Breast Cancer. 6: 29. PMID 32704531 DOI: 10.1038/s41523-020-0171-1 |
0.353 |
|
| 2020 |
Schito L, Rey S, Xu P, Man S, Cruz-Muñoz W, Kerbel RS. Metronomic chemotherapy offsets HIFα induction upon maximum-tolerated dose in metastatic cancers. Embo Molecular Medicine. e11416. PMID 32686360 DOI: 10.15252/Emmm.201911416 |
0.403 |
|
| 2020 |
Khan KA, Kerbel RS. A new Tie1 targeted antibody blocks tumor cell extravasation and metastasis. Embo Molecular Medicine. e12355. PMID 32406209 DOI: 10.15252/Emmm.202012355 |
0.438 |
|
| 2019 |
Muñoz R, Hileeto D, Cruz-Muñoz W, Wood GA, Xu P, Man S, Viloria-Petit A, Kerbel RS. Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion. Plos One. 14: e0222580. PMID 31536574 DOI: 10.1371/Journal.Pone.0222580 |
0.76 |
|
| 2019 |
Timaner M, Kotsofruk R, Raviv Z, Magidey K, Shechter D, Kan T, Nevelsky A, Daniel S, de Vries EGE, Zhang T, Kaidar-Person O, Kerbel RS, Shaked Y. Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1. Oncogene. PMID 31467431 DOI: 10.1038/S41388-019-0971-7 |
0.395 |
|
| 2019 |
Reguera-Nuñez E, Man S, Xu P, Hilberg F, Kerbel RS. Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity. Angiogenesis. PMID 31463627 DOI: 10.1007/S10456-019-09677-X |
0.447 |
|
| 2019 |
Miller IS, Shiels LP, Conroy E, Connor K, Dicker P, Gallagher WM, Donovan NO, Kerbel RS, Crown J, Byrne AT. Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents. Scientific Reports. 9: 9204. PMID 31235775 DOI: 10.1038/S41598-019-45444-0 |
0.444 |
|
| 2019 |
Kuczynski EA, Vermeulen PB, Pezzella F, Kerbel RS, Reynolds AR. Vessel co-option in cancer. Nature Reviews. Clinical Oncology. PMID 30816337 DOI: 10.1038/S41571-019-0181-9 |
0.376 |
|
| 2019 |
Reguera-Nuñez E, Xu P, Chow A, Man S, Hilberg F, Kerbel RS. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer. Journal of Experimental & Clinical Cancer Research : Cr. 38: 16. PMID 30635009 DOI: 10.1186/S13046-018-0999-5 |
0.403 |
|
| 2019 |
Phillips C, Francia G, Kerbel RS, Emmenegger U. Personalized use of metronomic cyclophosphamide for DNA repair deficient castration-resistant prostate cancer: A phase II trial. Journal of Clinical Oncology. 37: TPS346-TPS346. DOI: 10.1200/Jco.2019.37.7_Suppl.Tps346 |
0.357 |
|
| 2018 |
Wu FTH, Xu P, Chow A, Man S, Krüger J, Khan KA, Paez-Ribes M, Pham E, Kerbel RS. Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. British Journal of Cancer. PMID 30498230 DOI: 10.1038/S41416-018-0297-1 |
0.353 |
|
| 2018 |
O'Reilly MA, Chinnery T, Yee ML, Wu SK, Hynynen K, Kerbel RS, Czarnota GJ, Pritchard KI, Sahgal A. Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases. Scientific Reports. 8: 9013. PMID 29899537 DOI: 10.1038/S41598-018-27335-Y |
0.402 |
|
| 2018 |
Reguera-Nuñez E, Man S, Xu P, Kerbel RS. Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models. Angiogenesis. PMID 29786782 DOI: 10.1007/S10456-018-9623-8 |
0.506 |
|
| 2018 |
Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, ... ... Kerbel RS, et al. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. PMID 29766399 DOI: 10.1007/S10456-018-9613-X |
0.341 |
|
| 2018 |
Fricke IB, De Souza R, Costa Ayub L, Francia G, Kerbel R, Jaffray DA, Zheng J. Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice. Plos One. 13: e0196892. PMID 29723251 DOI: 10.1371/Journal.Pone.0196892 |
0.332 |
|
| 2018 |
Mastri M, Lee CR, Tracz A, Kerbel RS, Dolan M, Shi Y, Ebos JML. Tumor-independent host secretomes induced by angiogenesis and immune-checkpoint inhibitors. Molecular Cancer Therapeutics. PMID 29695634 DOI: 10.1158/1535-7163.Mct-17-1066 |
0.474 |
|
| 2018 |
Donnem T, Reynolds AR, Kuczynski EA, Gatter K, Vermeulen PB, Kerbel RS, Harris AL, Pezzella F. Non-angiogenic tumours and their influence on cancer biology. Nature Reviews. Cancer. PMID 29520090 DOI: 10.1038/Nrc.2018.14 |
0.363 |
|
| 2018 |
Kuczynski EA, Krueger J, Chow A, Xu P, Man S, Sundaravadanam Y, Miller JK, Krzyzanowski PM, Kerbel RS. Impact of chemical-induced mutational load increase on immune checkpoint therapy in poorly responsive murine tumors. Molecular Cancer Therapeutics. PMID 29483207 DOI: 10.1158/1535-7163.Mct-17-1091 |
0.39 |
|
| 2018 |
Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nature Reviews. Clinical Oncology. PMID 29434333 DOI: 10.1038/Nrclinonc.2018.9 |
0.397 |
|
| 2018 |
Lopez J, Valenzuela P, Gallegos V, Parra K, Rolih V, Garcia DG, Martinez J, Emmenegger U, Bocci G, Kerbel RS, Francia G. Abstract 10: Evaluation of metronomic chemotherapy regimens in preclinical orthotopically implanted colon cancer models, and in patient-derived xenografts Cancer Research. 78: 10-10. DOI: 10.1158/1538-7445.Am2018-10 |
0.393 |
|
| 2017 |
Rey S, Schito L, Wouters BG, Eliasof S, Kerbel RS. Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy. Trends in Cancer. 3: 529-541. PMID 28718406 DOI: 10.1016/J.Trecan.2017.05.002 |
0.395 |
|
| 2017 |
Khan KA, Kerbel RS. A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature. Cancer Cell. 31: 469-471. PMID 28399405 DOI: 10.1016/J.Ccell.2017.03.009 |
0.457 |
|
| 2017 |
Kerbel RS, Shaked Y. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease. Cancer Letters. PMID 28202353 DOI: 10.1016/J.Canlet.2017.02.005 |
0.496 |
|
| 2016 |
Pantziarka P, Hutchinson L, André N, Benzekry S, Bertolini F, Bhattacharjee A, Chiplunkar S, Duda DG, Gota V, Gupta S, Joshi A, Kannan S, Kerbel R, Kieran M, Palazzo A, et al. Next generation metronomic chemotherapy-report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. Ecancermedicalscience. 10: 689. PMID 27994645 DOI: 10.3332/Ecancer.2016.689 |
0.366 |
|
| 2016 |
Rana P, Pritchard KI, Kerbel R. Plasma vascular endothelial growth factor as a predictive biomarker: Door closed? European Journal of Cancer (Oxford, England : 1990). PMID 27916568 DOI: 10.1016/J.Ejca.2016.11.002 |
0.324 |
|
| 2016 |
Kuczynski EA, Kerbel RS. Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma. Chinese Journal of Cancer. 35: 97. PMID 27887628 DOI: 10.1186/S40880-016-0162-7 |
0.414 |
|
| 2016 |
Kerbel RS, Shaked Y. Therapy-activated stromal cells can dictate tumor fate. The Journal of Experimental Medicine. PMID 27881735 DOI: 10.1084/jem.20161845 |
0.359 |
|
| 2016 |
Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, Hegedus B, Hoetzenecker K, Renyi-Vamos F, Kuczynski EA, Vasudev NS, ... ... Kerbel RS, et al. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. The Journal of Pathology. PMID 27859259 DOI: 10.1002/Path.4845 |
0.376 |
|
| 2016 |
Wu FT, Paez-Ribes M, Xu P, Man S, Bogdanovic E, Thurston G, Kerbel RS. Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer. Scientific Reports. 6: 36694. PMID 27841282 DOI: 10.1038/Srep36694 |
0.432 |
|
| 2016 |
Wu FT, Man S, Xu P, Chow A, Paez-Ribes M, Lee CR, Pirie-Shepherd SR, Emmenegger U, Kerbel RS. Efficacy of co-targeting Angiopoietin-2 and the VEGF pathway in the adjuvant postsurgical setting for early breast, colorectal and renal cancers. Cancer Research. PMID 27651308 DOI: 10.1158/0008-5472.Can-16-0888 |
0.446 |
|
| 2016 |
Shaked Y, Pham E, Hariharan S, Magidey K, Beyar-Katz O, Xu P, Man S, Wu F, Miller V, Andrews DW, Kerbel RS. Evidence implicating immunological host effects in the efficacy of metronomic low-dose chemotherapy. Cancer Research. PMID 27569209 DOI: 10.1158/0008-5472.Can-16-0136 |
0.483 |
|
| 2016 |
Paez-Ribes M, Man S, Xu P, Kerbel RS. Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note. Plos One. 11: e0158034. PMID 27355476 DOI: 10.1371/Journal.Pone.0158034 |
0.462 |
|
| 2016 |
Pham E, Yin M, Peters CG, Lee CR, Brown D, Xu P, Man S, Jayaraman L, Rohde E, Chow A, Lazarus D, Eliasof S, Foster FS, Kerbel RS. Preclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle-drug conjugate, in treatment of metastatic triple-negative breast cancer. Cancer Research. PMID 27325647 DOI: 10.1158/0008-5472.CAN-15-3435 |
0.393 |
|
| 2016 |
Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nature Reviews. Clinical Oncology. PMID 27184418 DOI: 10.1038/Nrclinonc.2016.64 |
0.375 |
|
| 2016 |
Kuczynski EA, Yin M, Bar-Zion A, Lee CR, Butz H, Man S, Daley F, Vermeulen PB, Yousef GM, Foster FS, Reynolds AR, Kerbel RS. Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma. Journal of the National Cancer Institute. 108. PMID 27059374 DOI: 10.1093/Jnci/Djw030 |
0.459 |
|
| 2016 |
Jayson GC, Kerbel R, Ellis LM, Harris AL. Antiangiogenic therapy in oncology: current status and future directions. Lancet (London, England). PMID 26853587 DOI: 10.1016/S0140-6736(15)01088-0 |
0.435 |
|
| 2016 |
Alkins R, Burgess A, Kerbel R, Wels WS, Hynynen K. Early treatment of HER2-amplified brain tumors with targeted NK-92 cells and focused ultrasound improves survival. Neuro-Oncology. PMID 26819443 DOI: 10.1017/Cjn.2015.76 |
0.388 |
|
| 2016 |
Shiels LS, Miller IS, Morgan C, Cremona M, Kerbel R, Hennessey B, O’Donovan N, Crown J, Byrne AT. Abstract 3269: Recapitulating the BETH adjuvant breast cancer trial (NCT00625898) using clinically accurate orthotopic surgical resection models Cancer Research. 76: 3269-3269. DOI: 10.1158/1538-7445.Am2016-3269 |
0.382 |
|
| 2015 |
Di Desidero T, Xu P, Man S, Bocci G, Kerbel RS. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. Oncotarget. PMID 26623560 DOI: 10.18632/Oncotarget.6377 |
0.481 |
|
| 2015 |
Emmenegger U, Booth CM, Berry S, Sridhar SS, Winquist E, Bandali N, Chow A, Lee C, Xu P, Man S, Kerbel RS, Ko YJ. Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer. The Oncologist. PMID 26542984 DOI: 10.1634/Theoncologist.2015-0220 |
0.337 |
|
| 2015 |
Kerbel RS. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment. Cancer Journal (Sudbury, Mass.). 21: 274-83. PMID 26222079 DOI: 10.1097/Ppo.0000000000000134 |
0.502 |
|
| 2015 |
Paez-Ribes M, Man S, Xu P, Kerbel RS. Potential Pro-invasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26169967 DOI: 10.1158/1078-0432.Ccr-15-0915 |
0.417 |
|
| 2015 |
Kerbel RS, Grothey A. Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials. Nature Reviews. Clinical Oncology. 12: 313-4. PMID 25963090 DOI: 10.1038/Nrclinonc.2015.89 |
0.332 |
|
| 2015 |
Kuczynski EA, Lee CR, Man S, Chen E, Kerbel RS. Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. Cancer Research. 75: 2510-9. PMID 25908587 DOI: 10.1158/0008-5472.Can-14-3687 |
0.392 |
|
| 2015 |
Jedeszko C, Paez-Ribes M, Di Desidero T, Man S, Lee CR, Xu P, Bjarnason GA, Bocci G, Kerbel RS. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Science Translational Medicine. 7: 282ra50. PMID 25855496 DOI: 10.1126/Scitranslmed.3010722 |
0.466 |
|
| 2015 |
Wu FT, Lee CR, Bogdanovic E, Prodeus A, Gariépy J, Kerbel RS. Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2. Embo Molecular Medicine. 7: 770-87. PMID 25851538 DOI: 10.15252/Emmm.201404193 |
0.492 |
|
| 2015 |
Pham E, Birrer MJ, Eliasof S, Garmey EG, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, Krasner C, Kerbel RS. Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 808-18. PMID 25524310 DOI: 10.1158/1078-0432.Ccr-14-2810 |
0.43 |
|
| 2015 |
Ebos JML, Mastri M, Hudson JM, Lee CR, Tracz A, Attwood K, Burns PN, Kerbel RS, Bjarnason GA. Effect of the timing of sunitinib administration on the predictive value of biomarkers in renal cell cancer (mRCC). Journal of Clinical Oncology. 33: 11096-11096. DOI: 10.1200/Jco.2015.33.15_Suppl.11096 |
0.35 |
|
| 2015 |
Kerbel RS. Abstract IA22: Preclinical modeling of adjuvant and metastatic antiangiogenic therapy: Relevance for better predicting clinical outcomes Molecular Cancer Therapeutics. 14. DOI: 10.1158/1538-8514.Tumang15-Ia22 |
0.48 |
|
| 2015 |
Pham E, Lee CR, Xu P, Man S, Yin M, Foster FS, Peters CG, Lazarus D, Eliasof S, Kerbel RS. Abstract 4124: Potent anti-tumor and metastatic breast cancer efficacy of bevacizumab with CRLX101, an investigational chemotherapy nanoparticle-drug conjugate that secondarily suppresses HIF-1α Cancer Research. 75: 4124-4124. DOI: 10.1158/1538-7445.Am2015-4124 |
0.5 |
|
| 2014 |
Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P, Kerbel RS. Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy. Embo Molecular Medicine. 6: 1561-76. PMID 25361689 DOI: 10.15252/Emmm.201403989 |
0.446 |
|
| 2014 |
Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, Cavallaro U, Cinieri S, Colleoni M, Curigliano G, Di Desidero T, Eniu A, Fazio N, Kerbel R, et al. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. Ecancermedicalscience. 8: 463. PMID 25228919 DOI: 10.3332/Ecancer.2014.463 |
0.364 |
|
| 2014 |
Buckstein R, Kerbel R, Cheung M, Shaked Y, Chodirker L, Lee CR, Lenis M, Davidson C, Cussen MA, Reis M, Chesney A, Zhang L, Mamedov A, Wells RA. Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis. Leukemia Research. 38: 756-63. PMID 24819395 DOI: 10.1016/J.Leukres.2014.03.022 |
0.344 |
|
| 2014 |
Cruz-Muñoz W, Di Desidero T, Man S, Xu P, Jaramillo ML, Hashimoto K, Collins C, Banville M, O'Connor-McCourt MD, Kerbel RS. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer. Angiogenesis. 17: 661-73. PMID 24569856 DOI: 10.1007/S10456-014-9422-9 |
0.453 |
|
| 2014 |
Ardelean DS, Yin M, Jerkic M, Peter M, Ngan B, Kerbel RS, Foster FS, Letarte M. Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis. Angiogenesis. 17: 641-59. PMID 24510304 DOI: 10.1007/S10456-014-9421-X |
0.372 |
|
| 2014 |
Ardelean DS, Jerkic M, Yin M, Peter M, Ngan B, Kerbel RS, Foster FS, Letarte M. Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment. Angiogenesis. 17: 129-46. PMID 24061911 DOI: 10.1007/S10456-013-9383-4 |
0.396 |
|
| 2014 |
Chow A, Wong A, Francia G, Man S, Kerbel RS, Emmenegger U. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy Investigational New Drugs. 32: 47-59. PMID 23728939 DOI: 10.1007/S10637-013-9974-3 |
0.405 |
|
| 2014 |
Valenzuela PA, Jallad SN, Parra K, Lerma N, Miramontes I, Gallegos A, Xu P, Cruz-Munoz W, Man S, Kerbel RS, Francia G. Abstract 3142: Derivation and analysis of preclinical models of human her-2 positive breast cancer Cancer Research. 74: 3142-3142. DOI: 10.1158/1538-7445.Am2014-3142 |
0.405 |
|
| 2013 |
Torimura T, Iwamoto H, Nakamura T, Koga H, Ueno T, Kerbel RS, Sata M. Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. Translational Oncology. 6: 511-9. PMID 24151531 DOI: 10.1593/Tlo.13481 |
0.342 |
|
| 2013 |
Kerbel RS, Guerin E, Francia G, Xu P, Lee CR, Ebos JM, Man S. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. Breast (Edinburgh, Scotland). 22: S57-65. PMID 24074794 DOI: 10.1016/J.Breast.2013.07.011 |
0.453 |
|
| 2013 |
Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS. Drug rechallenge and treatment beyond progression--implications for drug resistance. Nature Reviews. Clinical Oncology. 10: 571-87. PMID 23999218 DOI: 10.1038/Nrclinonc.2013.158 |
0.373 |
|
| 2013 |
Di Desidero T, Fioravanti A, Orlandi P, Canu B, Giannini R, Borrelli N, Man S, Xu P, Fontanini G, Basolo F, Kerbel RS, Francia G, Danesi R, Bocci G. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. The Journal of Clinical Endocrinology and Metabolism. 98: E1465-73. PMID 23969186 DOI: 10.1210/Jc.2013-1364 |
0.33 |
|
| 2013 |
Milsom CC, Lee CR, Hackl C, Man S, Kerbel RS. Differential post-surgical metastasis and survival in SCID, NOD-SCID and NOD-SCID-IL-2Rγ(null) mice with parental and subline variants of human breast cancer: implications for host defense mechanisms regulating metastasis. Plos One. 8: e71270. PMID 23967178 DOI: 10.1371/Journal.Pone.0071270 |
0.338 |
|
| 2013 |
Di Matteo P, Hackl C, Jedeszko C, Valentinis B, Bordignon C, Traversari C, Kerbel RS, Rizzardi GP. NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells. British Journal of Cancer. 109: 360-9. PMID 23828516 DOI: 10.1038/Bjc.2013.347 |
0.385 |
|
| 2013 |
Morsi A, Gaziel-Sovran A, Cruz-Munoz W, Kerbel RS, Golfinos JG, Hernando E, Wadghiri YZ. Development and characterization of a clinically relevant mouse model of melanoma brain metastasis. Pigment Cell & Melanoma Research. 26: 743-5. PMID 23647875 DOI: 10.1111/Pcmr.12114 |
0.367 |
|
| 2013 |
Guerin E, Man S, Xu P, Kerbel RS. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Research. 73: 2743-8. PMID 23610448 DOI: 10.1158/0008-5472.Can-12-4183 |
0.401 |
|
| 2013 |
Alkins R, Burgess A, Ganguly M, Francia G, Kerbel R, Wels WS, Hynynen K. Focused ultrasound delivers targeted immune cells to metastatic brain tumors. Cancer Research. 73: 1892-9. PMID 23302230 DOI: 10.1158/0008-5472.Can-12-2609 |
0.397 |
|
| 2013 |
Todorova M, Agache V, Mortazavi O, Chen B, Karshafian R, Hynynen K, Man S, Kerbel RS, Goertz DE. Antitumor effects of combining metronomic chemotherapy with the antivascular action of ultrasound stimulated microbubbles. International Journal of Cancer. Journal International Du Cancer. 132: 2956-66. PMID 23225339 DOI: 10.1002/Ijc.27977 |
0.436 |
|
| 2013 |
Hackl C, Man S, Francia G, Milsom C, Xu P, Kerbel RS. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut. 62: 259-71. PMID 22543158 DOI: 10.1136/Gutjnl-2011-301585 |
0.345 |
|
| 2013 |
Kerbel RS. Abstract IA29: Models of postsurgical early and late stage metastasis for improving preclinical adjuvant and metastatic therapy investigations Cancer Research. 73. DOI: 10.1158/1538-7445.Tim2013-Ia29 |
0.448 |
|
| 2013 |
Kandela I, Ugolkov A, Francia G, Rabbani S, Kerbel RS, Mazar AP. Abstract 863: Inhibition of breast cancer metastaticprogression by a novel uPAR targeted monoclonal antibody, ATN-658, correlateswith the uPAR expression. Cancer Research. 73: 863-863. DOI: 10.1158/1538-7445.Am2013-863 |
0.459 |
|
| 2013 |
Eliasof S, Conley S, Keefe SM, Kerbel R, Krasner CN, Lazarus D, Peters C, Pham E, Wicha MS, Garmey EG. Abstract PR09: Synergistic activity of CRLX101, a nanopharmaceutical in Phase II clinical trials, with antiangiogenic therapies mediated through HIF-1alpha inhibition: A translational research program. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-Pr09 |
0.483 |
|
| 2012 |
Kerbel RS. Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. Journal of Mammary Gland Biology and Neoplasia. 17: 229-39. PMID 23011602 DOI: 10.1007/S10911-012-9266-0 |
0.412 |
|
| 2012 |
Cruz-Muñoz W, Jaramillo ML, Man S, Xu P, Banville M, Collins C, Nantel A, Francia G, Morgan SS, Cranmer LD, O'Connor-McCourt MD, Kerbel RS. Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Research. 72: 4909-19. PMID 22865454 DOI: 10.1158/0008-5472.Can-12-2194 |
0.421 |
|
| 2012 |
Allegrini G, Di Desidero T, Barletta MT, Fioravanti A, Orlandi P, Canu B, Chericoni S, Loupakis F, Di Paolo A, Masi G, Fontana A, Lucchesi S, Arrighi G, Giusiani M, Ciarlo A, ... ... Kerbel RS, et al. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis. 15: 275-86. PMID 22382585 DOI: 10.1007/S10456-012-9260-6 |
0.312 |
|
| 2012 |
Mackey JR, Kerbel RS, Gelmon KA, McLeod DM, Chia SK, Rayson D, Verma S, Collins LL, Paterson AH, Robidoux A, Pritchard KI. Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. Cancer Treatment Reviews. 38: 673-88. PMID 22365657 DOI: 10.1016/J.Ctrv.2011.12.002 |
0.379 |
|
| 2012 |
Francia G, Shaked Y, Hashimoto K, Sun J, Yin M, Cesta C, Xu P, Man S, Hackl C, Stewart J, Uhlik M, Dantzig AH, Foster FS, Kerbel RS. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Molecular Cancer Therapeutics. 11: 680-9. PMID 22188817 DOI: 10.1158/1535-7163.Mct-11-0659 |
0.493 |
|
| 2012 |
Morsi AM, Gazial-Sovran A, Baig H, Kerbel RS, Golfinos J, Wadghiri YZ, Hernando E. Newmouse models of melanoma metastasis and differences in brain tropism and metastatic growth pattern. Journal of Clinical Oncology. 30: e19015-e19015. DOI: 10.1200/Jco.2012.30.15_Suppl.E19015 |
0.318 |
|
| 2012 |
Emmenegger U, Booth CM, Berry SR, Sridhar SS, Winquist E, Bandali N, Chow A, Lee CR, Xu P, Man S, Kerbel RS, Ko Y. Temsirolimus (TEM) maintenance therapy after response of castration-resistant prostate cancer (CRPC) to docetaxel (TAX). Journal of Clinical Oncology. 30: e15177-e15177. DOI: 10.1200/Jco.2012.30.15_Suppl.E15177 |
0.33 |
|
| 2012 |
Francia G, Rodriguez C, Xu P, Man S, Cruz-Munoz W, Bocci G, Kerbel RS. Development of preclinical models of human BT474 and MDA-MB-361 breast cancer that endogenously overexpress HER2 and that respond to trastuzumab. Journal of Clinical Oncology. 30: e11061-e11061. DOI: 10.1200/Jco.2012.30.15_Suppl.E11061 |
0.418 |
|
| 2012 |
Matteo PD, Hackl C, Jedeszko C, Porcellini S, Valentinis B, Bordignon C, Traversari C, Kerbel RS, Rizzardi G. Abstract 4381: The novel direct-acting vascular targeting agent NGR-TNF exertsin vivoantitumor activity by inducing endothelial and tumor cell death in the absence of proangiogenic bone-marrow derived cell recruitment Cancer Research. 72: 4381-4381. DOI: 10.1158/1538-7445.Am2012-4381 |
0.493 |
|
| 2012 |
Francia G, Shaked Y, Hashimoto K, Sun J, Xu P, Man S, Hackl C, Stewart J, Dantzig AH, Uhlik M, Foster S, Kerbel RS. Abstract 4377: Metronomic oral prodrug of gemcitabine (LY2334737) causes antitumor effects with concomitant increase in intratumoral blood flow Cancer Research. 72: 4377-4377. DOI: 10.1158/1538-7445.Am2012-4377 |
0.486 |
|
| 2012 |
Ebos JML, Lee CR, Cruz-Munoz W, Jedeszko C, Kerbel RS. Abstract 1375: Contrasting effects of VEGF pathway inhibitors in primary and metastatic disease using perioperative neoadjuvant mouse models Cancer Research. 72: 1375-1375. DOI: 10.1158/1538-7445.Am2012-1375 |
0.523 |
|
| 2011 |
Bjarnason GA, Williams R, Hudson JM, Bailey C, Lee CR, Lloyd BA, Kandel S, Ebos JM, Kiss A, Kerbel RS, Milot LM, Atri M, Stanisz GJ, Burns P. Microbubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for the assessment of vascular response to sunitinib in renal cell carcinoma (RCC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4627. PMID 28023976 DOI: 10.1200/Jco.2011.29.15_Suppl.4627 |
0.329 |
|
| 2011 |
Cao Y, Arbiser J, D'Amato RJ, D'Amore PA, Ingber DE, Kerbel R, Klagsbrun M, Lim S, Moses MA, Zetter B, Dvorak H, Langer R. Forty-year journey of angiogenesis translational research. Science Translational Medicine. 3: 114rv3. PMID 22190240 DOI: 10.1126/Scitranslmed.3003149 |
0.407 |
|
| 2011 |
Kerbel RS. Reappraising antiangiogenic therapy for breast cancer. Breast (Edinburgh, Scotland). 20: S56-60. PMID 22015294 DOI: 10.1016/S0960-9776(11)70295-8 |
0.425 |
|
| 2011 |
Schmid MC, Avraamides CJ, Foubert P, Shaked Y, Kang SW, Kerbel RS, Varner JA. Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Research. 71: 6965-75. PMID 21948958 DOI: 10.1158/0008-5472.Can-11-0588 |
0.423 |
|
| 2011 |
Kumar S, Mokhtari RB, Sheikh R, Wu B, Zhang L, Xu P, Man S, Oliveira ID, Yeger H, Kerbel RS, Baruchel S. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 5656-67. PMID 21788355 DOI: 10.1158/1078-0432.Ccr-11-0078 |
0.517 |
|
| 2011 |
Voloshin T, Gingis-Velitski S, Bril R, Benayoun L, Munster M, Milsom C, Man S, Kerbel RS, Shaked Y. G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood. 118: 3426-35. PMID 21685373 DOI: 10.1182/Blood-2010-11-320812 |
0.424 |
|
| 2011 |
Iwamoto H, Torimura T, Nakamura T, Hashimoto O, Inoue K, Kurogi J, Niizeki T, Kuwahara R, Abe M, Koga H, Yano H, Kerbel RS, Ueno T, Sata M. Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. Neoplasia (New York, N.Y.). 13: 187-97. PMID 21390182 DOI: 10.1593/Neo.101186 |
0.372 |
|
| 2011 |
Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nature Reviews. Clinical Oncology. 8: 210-21. PMID 21364524 DOI: 10.1038/Nrclinonc.2011.21 |
0.362 |
|
| 2011 |
Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nature Reviews. Cancer. 11: 135-41. PMID 21258397 DOI: 10.1038/Nrc3001 |
0.344 |
|
| 2011 |
Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia (New York, N.Y.). 13: 40-8. PMID 21245939 DOI: 10.1593/Neo.101174 |
0.393 |
|
| 2011 |
Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biology & Therapy. 11: 373-82. PMID 21150278 DOI: 10.4161/Cbt.11.4.14097 |
0.396 |
|
| 2011 |
Cruz-Muñoz W, Kerbel RS. Preclinical approaches to study the biology and treatment of brain metastases. Seminars in Cancer Biology. 21: 123-30. PMID 21147227 DOI: 10.1016/J.Semcancer.2010.12.001 |
0.375 |
|
| 2011 |
Matteo PD, Hackl C, Jedeszko C, Valentinis B, Bordignon C, Traversari C, Kerbel RS, Rizzardi G. Abstract 4249: NGR-TNF, a novel direct-acting vascular targeting agent, does not induce “cytokine-rebound” recruitment of pro-angiogenic bone-marrow derived cells Cancer Research. 71: 4249-4249. DOI: 10.1158/1538-7445.Am2011-4249 |
0.472 |
|
| 2010 |
Emmenegger U, Kerbel RS. Cancer: Chemotherapy counteracted. Nature. 468: 637-8. PMID 21124441 DOI: 10.1038/468637A |
0.354 |
|
| 2010 |
Tang TC, Man S, Xu P, Francia G, Hashimoto K, Emmenegger U, Kerbel RS. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia (New York, N.Y.). 12: 928-40. PMID 21076618 DOI: 10.1593/Neo.10804 |
0.4 |
|
| 2010 |
Kerbel RS, Ebos JM. Peering into the aftermath: The inhospitable host? Nature Medicine. 16: 1084-5. PMID 20930748 DOI: 10.1038/Nm1010-1084 |
0.461 |
|
| 2010 |
Hashimoto K, Man S, Xu P, Cruz-Munoz W, Tang T, Kumar R, Kerbel RS. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Molecular Cancer Therapeutics. 9: 996-1006. PMID 20371722 DOI: 10.1158/1535-7163.Mct-09-0960 |
0.45 |
|
| 2010 |
Tang TC, Man S, Lee CR, Xu P, Kerbel RS. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia (New York, N.Y.). 12: 264-74. PMID 20234820 DOI: 10.1593/Neo.91872 |
0.381 |
|
| 2010 |
Langenberg MH, Nijkamp MW, Roodhart JM, Snoeren N, Tang T, Shaked Y, van Hillegersberg R, Witteveen PO, Vermaat JS, Kranenburg O, Kerbel RS, Medema RH, Borel Rinkes IH, Voest EE. Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF. Cancer Biology & Therapy. 9: 743-8. PMID 20215863 DOI: 10.4161/Cbt.9.9.11551 |
0.382 |
|
| 2010 |
Mamluk R, Carvajal IM, Morse BA, Wong H, Abramowitz J, Aslanian S, Lim AC, Gokemeijer J, Storek MJ, Lee J, Gosselin M, Wright MC, Camphausen RT, Wang J, Chen Y, ... ... Kerbel R, et al. Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2. Mabs. 2: 199-208. PMID 20190562 DOI: 10.4161/Mabs.2.2.11304 |
0.415 |
|
| 2010 |
Emmenegger U, Francia G, Shaked Y, Kerbel RS. Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer. Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 180: 165-83. PMID 20033383 DOI: 10.1007/978-3-540-78281-0_10 |
0.427 |
|
| 2010 |
Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, Sutherland DJ, Emmenegger U, Slingerland J, Gardner S, Pritchard KI. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 723-30. PMID 20026801 DOI: 10.1200/Jco.2009.24.0143 |
0.4 |
|
| 2010 |
Bjarnason GA, Hudson JM, Bailey C, Lee CR, Williams R, Lloyd BA, Kerbel R, Stanisz GJ, Atri M, Burns P. Microbubble ultrasound compared to dynamic contrast MRI and CT for the assessment of vascular response to sunitinib in renal cell carcinoma. Journal of Clinical Oncology. 28: e15039-e15039. DOI: 10.1200/Jco.2010.28.15_Suppl.E15039 |
0.384 |
|
| 2010 |
Milsom CC, Shaked Y, Lee CR, Man S, Kerbel RS. Abstract 382: Platelets are implicated in the rapid host responses induced by cytotoxic chemotherapy which limit its anti-tumor efficacy Cancer Research. 70: 382-382. DOI: 10.1158/1538-7445.Am10-382 |
0.382 |
|
| 2010 |
Cruz W, Man S, Jaramillo M, O'Connor-McCourt M, Banville M, Kerbel RS. Abstract 1452: Examination of mechanisms involved in spontaneous melanoma metastasis to CNS Cancer Research. 70: 1452-1452. DOI: 10.1158/1538-7445.Am10-1452 |
0.392 |
|
| 2010 |
Folkins C, Kerbel RS. Cancer Stem Cells Promote Tumor Vascular Development - Response Cancer Research. 70: 3412-3412. DOI: 10.1158/0008-5472.Can-10-0337 |
0.399 |
|
| 2010 |
Kerbel R, Ebos J, Shaked Y. 460 Antiangiogenic drug alterations of the tumor microenvironment which can impact chemotherapy efficacy European Journal of Cancer Supplements. 8: 149. DOI: 10.1016/S1359-6349(10)72167-4 |
0.424 |
|
| 2010 |
Shaked Y, Nathan P, Daenen LGM, Kerbel RS. Combining antiangiogenic drugs with vascular disrupting agents rationale and mechanisms of action Vascular Disruptive Agents For the Treatment of Cancer. 117-134. DOI: 10.1007/978-1-4419-6609-4_6 |
0.428 |
|
| 2009 |
Kerbel RS. Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast (Edinburgh, Scotland). 18: S41-7. PMID 19914541 DOI: 10.1016/S0960-9776(09)70271-1 |
0.498 |
|
| 2009 |
Francia G, Man S, Lee CJ, Lee CR, Xu P, Mossoba ME, Emmenegger U, Medin JA, Kerbel RS. Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6358-66. PMID 19825954 DOI: 10.1158/1078-0432.Ccr-09-0931 |
0.337 |
|
| 2009 |
Daenen LG, Shaked Y, Man S, Xu P, Voest EE, Hoffman RM, Chaplin DJ, Kerbel RS. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Molecular Cancer Therapeutics. 8: 2872-81. PMID 19825805 DOI: 10.1158/1535-7163.Mct-09-0583 |
0.527 |
|
| 2009 |
Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, Hoffman RM, Kerbel RS. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. Cancer Research. 69: 7243-51. PMID 19738068 DOI: 10.1158/0008-5472.Can-09-0167 |
0.492 |
|
| 2009 |
Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, Xu P, Cai SR, Arbeit JM, Voest EE, Chaplin DJ, Smythe J, Harris A, Nathan P, Judson I, Rustin G, ... ... Kerbel RS, et al. Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Research. 69: 7524-8. PMID 19738066 DOI: 10.1158/0008-5472.Can-09-0381 |
0.461 |
|
| 2009 |
Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5020-5. PMID 19671869 DOI: 10.1158/1078-0432.Ccr-09-0095 |
0.496 |
|
| 2009 |
Viloria-Petit AM, David L, Jia JY, Erdemir T, Bane AL, Pinnaduwage D, Roncari L, Narimatsu M, Bose R, Moffat J, Wong JW, Kerbel RS, O'Malley FP, Andrulis IL, Wrana JL. A role for the TGFbeta-Par6 polarity pathway in breast cancer progression. Proceedings of the National Academy of Sciences of the United States of America. 106: 14028-33. PMID 19667198 DOI: 10.1073/Pnas.0906796106 |
0.706 |
|
| 2009 |
Cruz-Munoz W, Man S, Kerbel RS. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 4867-74. PMID 19622578 DOI: 10.1158/1078-0432.Ccr-08-3275 |
0.361 |
|
| 2009 |
Bertolini F, Mancuso P, Braidotti P, Shaked Y, Kerbel RS. The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer. Biochimica Et Biophysica Acta. 1796: 27-32. PMID 19406208 DOI: 10.1016/J.Bbcan.2009.04.003 |
0.416 |
|
| 2009 |
Mutsaers AJ, Francia G, Man S, Lee CR, Ebos JM, Wu Y, Witte L, Berry S, Moore M, Kerbel RS. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 2397-405. PMID 19276250 DOI: 10.1158/1078-0432.Ccr-08-1627 |
0.402 |
|
| 2009 |
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15: 232-9. PMID 19249681 DOI: 10.1016/J.Ccr.2009.01.021 |
0.499 |
|
| 2009 |
Al-Nedawi K, Meehan B, Kerbel RS, Allison AC, Rak J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proceedings of the National Academy of Sciences of the United States of America. 106: 3794-9. PMID 19234131 DOI: 10.1073/Pnas.0804543106 |
0.468 |
|
| 2009 |
Francia G, Emmenegger U, Kerbel RS. Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy. Cancer Cell. 15: 3-5. PMID 19111874 DOI: 10.1016/J.Ccr.2008.12.011 |
0.506 |
|
| 2009 |
Mutsaers AJ, Man S, Xu P, Tikhomirov I, Kerbel RS. Abstract C49: Combination treatment with metronomic cyclophosphamide and the EGFR monoclonal antibody nimotuzumab is efficacious and non‐toxic in a preclinical model of advanced triple negative breast cancer Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C49 |
0.462 |
|
| 2008 |
Francia G, Emmenegger U, Lee CR, Shaked Y, Folkins C, Mossoba M, Medin JA, Man S, Zhu Z, Witte L, Kerbel RS. Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. Molecular Cancer Therapeutics. 7: 3452-9. PMID 18852148 DOI: 10.1158/1535-7163.Mct-08-0200 |
0.398 |
|
| 2008 |
Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, ... ... Kerbel RS, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell. 14: 263-73. PMID 18772115 DOI: 10.1016/J.Ccr.2008.08.001 |
0.452 |
|
| 2008 |
Kerbel RS, Benezra R, Lyden DC, Hattori K, Heissig B, Nolan DJ, Mittal V, Shaked Y, Dias S, Bertolini F, Rafii S. Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proceedings of the National Academy of Sciences of the United States of America. 105: E54; author reply E5. PMID 18715995 DOI: 10.1073/Pnas.0804876105 |
0.43 |
|
| 2008 |
Cruz-Munoz W, Man S, Xu P, Kerbel RS. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Research. 68: 4500-5. PMID 18559492 DOI: 10.1158/0008-5472.Can-08-0041 |
0.401 |
|
| 2008 |
Kuwai T, Nakamura T, Sasaki T, Kim SJ, Fan D, Villares GJ, Zigler M, Wang H, Bar-Eli M, Kerbel RS, Fidler IJ. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia (New York, N.Y.). 10: 489-500. PMID 18472966 DOI: 10.1593/Neo.08200 |
0.447 |
|
| 2008 |
Kerbel RS. Tumor angiogenesis. The New England Journal of Medicine. 358: 2039-49. PMID 18463380 DOI: 10.1056/NEJMra0706596 |
0.319 |
|
| 2008 |
Bocci G, Falcone A, Fioravanti A, Orlandi P, Di Paolo A, Fanelli G, Viacava P, Naccarato AG, Kerbel RS, Danesi R, Del Tacca M, Allegrini G. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. British Journal of Cancer. 98: 1619-29. PMID 18443598 DOI: 10.1038/Sj.Bjc.6604352 |
0.436 |
|
| 2008 |
Doñate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS, Mazar AP. Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 2137-44. PMID 18381955 DOI: 10.1158/1078-0432.Ccr-07-4530 |
0.32 |
|
| 2008 |
Allegrini G, Falcone A, Fioravanti A, Barletta MT, Orlandi P, Loupakis F, Cerri E, Masi G, Di Paolo A, Kerbel RS, Danesi R, Del Tacca M, Bocci G. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. British Journal of Cancer. 98: 1312-9. PMID 18362940 DOI: 10.1038/Sj.Bjc.6604311 |
0.316 |
|
| 2008 |
Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Research. 68: 521-9. PMID 18199548 DOI: 10.1158/0008-5472.Can-07-3217 |
0.494 |
|
| 2008 |
Bono A, Quarna J, Marighetti P, Calleri A, Antoniotti P, Mancuso P, Voest EE, Langenberg M, Roodhart J, Shaked Y, Kerbel RS, Bertolini F. Taxanes Induce a Rapid Mobilization of Different Populations of Circulating Endothelial Progenitors by SDF-1 Modulation in Cancer Patients. Blood. 112: 1885-1885. DOI: 10.1182/BLOOD.V112.11.1885.1885 |
0.331 |
|
| 2007 |
Kerbel RS. Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. Cancer Research and Treatment : Official Journal of Korean Cancer Association. 39: 150-9. PMID 19746237 DOI: 10.4143/Crt.2007.39.4.150 |
0.446 |
|
| 2007 |
Rychak JJ, Graba J, Cheung AM, Mystry BS, Lindner JR, Kerbel RS, Foster FS. Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis. Molecular Imaging. 6: 289-96. PMID 18092513 DOI: 10.2310/7290.2007.00024 |
0.416 |
|
| 2007 |
Ciarrocchi A, Jankovic V, Shaked Y, Nolan DJ, Mittal V, Kerbel RS, Nimer SD, Benezra R. Id1 restrains p21 expression to control endothelial progenitor cell formation. Plos One. 2: e1338. PMID 18092003 DOI: 10.1371/Journal.Pone.0001338 |
0.441 |
|
| 2007 |
Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proceedings of the National Academy of Sciences of the United States of America. 104: 17069-74. PMID 17942672 DOI: 10.1073/Pnas.0708148104 |
0.493 |
|
| 2007 |
Bertolini F, Mancuso P, Shaked Y, Kerbel RS. Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discovery Today. 12: 806-12. PMID 17933680 DOI: 10.1016/J.Drudis.2007.08.011 |
0.411 |
|
| 2007 |
Bosch-Marce M, Okuyama H, Wesley JB, Sarkar K, Kimura H, Liu YV, Zhang H, Strazza M, Rey S, Savino L, Zhou YF, McDonald KR, Na Y, Vandiver S, Rabi A, ... ... Kerbel R, et al. Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia. Circulation Research. 101: 1310-8. PMID 17932327 DOI: 10.1161/Circresaha.107.153346 |
0.353 |
|
| 2007 |
Man S, Munoz R, Kerbel RS. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Reviews. 26: 737-47. PMID 17846863 DOI: 10.1007/S10555-007-9087-6 |
0.441 |
|
| 2007 |
Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Research. 67: 7055-8. PMID 17671170 DOI: 10.1158/0008-5472.Can-07-0905 |
0.497 |
|
| 2007 |
Emmenegger U, Shaked Y, Man S, Bocci G, Spasojevic I, Francia G, Kouri A, Coke R, Cruz-Munoz W, Ludeman SM, Colvin OM, Kerbel RS. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Molecular Cancer Therapeutics. 6: 2280-9. PMID 17671082 DOI: 10.1158/1535-7163.Mct-07-0181 |
0.34 |
|
| 2007 |
Loupakis F, Falcone A, Masi G, Fioravanti A, Kerbel RS, Del Tacca M, Bocci G. Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 1816-8. PMID 17470880 DOI: 10.1200/Jco.2006.10.3051 |
0.369 |
|
| 2007 |
Cheung AM, Brown AS, Cucevic V, Roy M, Needles A, Yang V, Hicklin DJ, Kerbel RS, Foster FS. Detecting vascular changes in tumour xenografts using micro-ultrasound and micro-ct following treatment with VEGFR-2 blocking antibodies. Ultrasound in Medicine & Biology. 33: 1259-68. PMID 17467156 DOI: 10.1016/J.Ultrasmedbio.2007.01.015 |
0.351 |
|
| 2007 |
Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Research. 67: 3560-4. PMID 17440065 DOI: 10.1158/0008-5472.Can-06-4238 |
0.488 |
|
| 2007 |
Cervi D, Shaked Y, Haeri M, Usenko T, Lee CR, Haigh JJ, Nagy A, Kerbel RS, Yefenof E, Ben-David Y. Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia. Blood. 109: 2139-46. PMID 17053052 DOI: 10.1182/Blood-2005-11-026823 |
0.352 |
|
| 2006 |
Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nature Reviews. Cancer. 6: 835-45. PMID 17036040 DOI: 10.1038/Nrc1971 |
0.428 |
|
| 2006 |
Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, Hicklin DJ, Chaplin D, Foster FS, Benezra R, Kerbel RS. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science (New York, N.Y.). 313: 1785-7. PMID 16990548 DOI: 10.1126/Science.1127592 |
0.497 |
|
| 2006 |
Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M. High-Dose celecoxib and metronomic "low-dose" cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non-Hodgkin's lymphoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5190-8. PMID 16951238 DOI: 10.1158/1078-0432.Ccr-06-0474 |
0.355 |
|
| 2006 |
Shaked Y, Bertolini F, Emmenegger U, Lee CR, Kerbel RS. On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4040; author reply 4. PMID 16921064 DOI: 10.1200/Jco.2006.07.1175 |
0.371 |
|
| 2006 |
Ng SS, Sparreboom A, Shaked Y, Lee C, Man S, Desai N, Soon-Shiong P, Figg WD, Kerbel RS. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4331-8. PMID 16857808 DOI: 10.1158/1078-0432.Ccr-05-2762 |
0.408 |
|
| 2006 |
Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science (New York, N.Y.). 312: 1171-5. PMID 16728631 DOI: 10.1126/Science.1125950 |
0.479 |
|
| 2006 |
Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS, Kerbel RS. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Research. 66: 3639-48. PMID 16585189 DOI: 10.1158/0008-5472.Can-05-3295 |
0.483 |
|
| 2006 |
Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, Kerbel RS. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Research. 66: 3386-91. PMID 16585158 DOI: 10.1158/0008-5472.Can-05-4411 |
0.444 |
|
| 2006 |
Mancuso P, Colleoni M, Calleri A, Orlando L, Maisonneuve P, Pruneri G, Agliano A, Goldhirsch A, Shaked Y, Kerbel RS, Bertolini F. Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood. 108: 452-9. PMID 16543470 DOI: 10.1182/Blood-2005-11-4570 |
0.402 |
|
| 2006 |
du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 904-16. PMID 16467105 DOI: 10.1158/1078-0432.Ccr-05-1109 |
0.69 |
|
| 2006 |
Emmenegger U, Morton GC, Francia G, Shaked Y, Franco M, Weinerman A, Man S, Kerbel RS. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Research. 66: 1664-74. PMID 16452226 DOI: 10.1158/0008-5472.Can-05-2598 |
0.478 |
|
| 2006 |
Emmenegger U, Kerbel RS. A dynamic de-escalating dosing strategy to determine the optimal biological dose for antiangiogenic drugs. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7589-92. PMID 16278375 DOI: 10.1158/1078-0432.Ccr-05-1387 |
0.342 |
|
| 2006 |
Emmenegger U, Chen L, Shaked Y, Francia G, Kouri A, Mutsaers AJ, Ebos JM, Man S, Kerbel RS. Mechanisms of resistance to low-dose metronomic cyclophosphamide Journal of Clinical Oncology. 24: 13079-13079. DOI: 10.1200/Jco.2006.24.18_Suppl.13079 |
0.452 |
|
| 2006 |
Mutsaers A, Ebos J, Lee C, Francia G, Man S, Hicklin D, Iznaga-Escobar N, Kerbel R. 217 POSTER Circulating levels of ligand as a potential biomarker for optimal dosing of targeted antibody drugs to the epidermal growth factor receptor European Journal of Cancer Supplements. 4: 67-68. DOI: 10.1016/S1359-6349(06)70222-1 |
0.317 |
|
| 2005 |
Buckman RA, Wong NS, Clemons M, Verma S, Trudeau ME, Roche K, Kerbel RS, Deboer G, Sutherland DJ, Pritchard KI. Phase I-II study of DalCM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 695. PMID 27946215 DOI: 10.1200/Jco.2005.23.16_Suppl.695 |
0.3 |
|
| 2005 |
Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 438: 967-74. PMID 16355214 DOI: 10.1038/Nature04483 |
0.374 |
|
| 2005 |
Shaked Y, Bocci G, Munoz R, Man S, Ebos JM, Hicklin DJ, Bertolini F, D'Amato R, Kerbel RS. Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. Current Cancer Drug Targets. 5: 551-9. PMID 16305351 DOI: 10.2174/156800905774574020 |
0.455 |
|
| 2005 |
Francia G, Green SK, Bocci G, Man S, Emmenegger U, Ebos JML, Weinerman A, Shaked Y, Kerbel RS. Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: Implications for multicellular resistance to alkylating agents Molecular Cancer Therapeutics. 4: 1484-1494. PMID 16227397 DOI: 10.1158/1535-7163.Mct-04-0214 |
0.461 |
|
| 2005 |
Kerbel RS. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell. 8: 269-71. PMID 16226701 DOI: 10.1016/J.Ccr.2005.09.016 |
0.514 |
|
| 2005 |
Munoz R, Shaked Y, Bertolini F, Emmenegger U, Man S, Kerbel RS. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast (Edinburgh, Scotland). 14: 466-79. PMID 16199161 DOI: 10.1016/J.Breast.2005.08.026 |
0.403 |
|
| 2005 |
Yap R, Veliceasa D, Emmenegger U, Kerbel RS, McKay LM, Henkin J, Volpert OV. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: A complementation antiangiogenic strategy Clinical Cancer Research. 11: 6678-6685. PMID 16166447 DOI: 10.1158/1078-0432.Ccr-05-0621 |
0.424 |
|
| 2005 |
Liu Z, Li H, Derouet M, Filmus J, LaCasse EC, Korneluk RG, Kerbel RS, Rosen KV. ras Oncogene triggers up-regulation of cIAP2 and XIAP in intestinal epithelial cells: epidermal growth factor receptor-dependent and -independent mechanisms of ras-induced transformation. The Journal of Biological Chemistry. 280: 37383-92. PMID 16115895 DOI: 10.1074/Jbc.M503724200 |
0.338 |
|
| 2005 |
Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Research. 65: 7045-51. PMID 16103050 DOI: 10.1158/0008-5472.Can-05-0765 |
0.427 |
|
| 2005 |
Shaked Y, Emmenegger U, Man S, Cervi D, Bertolini F, Ben-David Y, Kerbel RS. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood. 106: 3058-61. PMID 15998832 DOI: 10.1182/Blood-2005-04-1422 |
0.431 |
|
| 2005 |
Rak J, Kerbel RS. Basic fibroblast growth factor and the complexity of tumour angiogenesis. Expert Opinion On Investigational Drugs. 7: 797-801. PMID 15991969 DOI: 10.1517/13543784.7.5.797 |
0.354 |
|
| 2005 |
Ma L, Francia G, Viloria-Petit A, Hicklin DJ, du Manoir J, Rak J, Kerbel RS. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Research. 65: 5365-73. PMID 15958585 DOI: 10.1158/0008-5472.Can-04-3156 |
0.737 |
|
| 2005 |
Bocci G, Tuccori M, Emmenegger U, Liguori V, Falcone A, Kerbel RS, Del Tacca M. Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 16: 1243-52. PMID 15905308 DOI: 10.1093/Annonc/Mdi240 |
0.355 |
|
| 2005 |
Voskas D, Jones N, Van Slyke P, Sturk C, Chang W, Haninec A, Babichev YO, Tran J, Master Z, Chen S, Ward N, Cruz M, Jones J, Kerbel RS, Jothy S, et al. A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. The American Journal of Pathology. 166: 843-55. PMID 15743796 DOI: 10.1016/S0002-9440(10)62305-X |
0.591 |
|
| 2005 |
Shaked Y, Cervi D, Neuman M, Chen L, Klement G, Michaud CR, Haeri M, Pak BJ, Kerbel RS, Ben-David Y. The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells. Blood. 105: 4500-7. PMID 15701719 DOI: 10.1182/Blood-2004-08-3210 |
0.421 |
|
| 2005 |
Davidoff AM, Ng CYC, Zhang Y, Streck CJ, Mabry SJ, Barton SH, Baudino T, Zhou J, Kerbel RS, Vanin EF, Nathwani AC. Careful decoy receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability Molecular Therapy. 11: 300-310. PMID 15668142 DOI: 10.1016/J.Ymthe.2004.09.014 |
0.506 |
|
| 2005 |
Shaked Y, Bertolini F, Man S, Rogers MS, Cervi D, Foutz T, Rawn K, Voskas D, Dumont DJ, Ben-David Y, Lawler J, Henkin J, Huber J, Hicklin DJ, D'Amato RJ, ... Kerbel RS, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell. 7: 101-11. PMID 15652753 DOI: 10.1016/J.Ccr.2004.11.023 |
0.401 |
|
| 2005 |
Mu oz R, Shaked Y, Emmenegger U, Man S, Kerbel R. S7 Combination cyclophosphamide — UFT metronomic low-dose chemotherapy for the treatment of metastatic breast cancer: A preclinical analysis The Breast. 14: S4-S5. DOI: 10.1016/S0960-9776(05)80008-6 |
0.317 |
|
| 2004 |
Watanabe H, Mamelak AJ, Wang B, Howell BG, Freed I, Esche C, Nakayama M, Nagasaki G, Hicklin DJ, Kerbel RS, Sauder DN. Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity. Experimental Dermatology. 13: 671-81. PMID 15500639 DOI: 10.1111/J.0906-6705.2004.00240.X |
0.345 |
|
| 2004 |
Kerbel RS. Vasohibin: the feedback on a new inhibitor of angiogenesis. The Journal of Clinical Investigation. 114: 884-6. PMID 15467823 DOI: 10.1172/Jci23153 |
0.402 |
|
| 2004 |
Bocci G, Man S, Green SK, Francia G, Ebos JML, Du Manoir JM, Weinerman A, Emmenegger U, Ma L, Thorpe P, Davidoff A, Huber J, Hicklin DJ, Kerbel RS. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies Cancer Research. 64: 6616-6625. PMID 15374976 DOI: 10.1158/0008-5472.Can-04-0401 |
0.435 |
|
| 2004 |
Francia G, Man S, Teicher B, Grasso L, Kerbel RS. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Molecular and Cellular Biology. 24: 6837-49. PMID 15254249 DOI: 10.1128/Mcb.24.15.6837-6849.2004 |
0.418 |
|
| 2004 |
Ebos JM, Bocci G, Man S, Thorpe PE, Hicklin DJ, Zhou D, Jia X, Kerbel RS. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Molecular Cancer Research : McR. 2: 315-26. PMID 15235107 |
0.314 |
|
| 2004 |
Vande Woude GF, Kelloff GJ, Ruddon RW, Koo HM, Sigman CC, Barrett JC, Day RW, Dicker AP, Kerbel RS, Parkinson DR, Slichenmyer WJ. Reanalysis of cancer drugs: old drugs, new tricks. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3897-907. PMID 15173099 DOI: 10.1158/1078-0432.Ccr-03-0786 |
0.365 |
|
| 2004 |
Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3885-96. PMID 15173098 DOI: 10.1158/1078-0432.Ccr-03-0785 |
0.342 |
|
| 2004 |
Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 3881-4. PMID 15173097 DOI: 10.1158/1078-0432.Ccr-03-0783 |
0.342 |
|
| 2004 |
Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, Kerbel RS. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Research. 64: 3994-4000. PMID 15173013 DOI: 10.1158/0008-5472.Can-04-0580 |
0.387 |
|
| 2004 |
Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nature Reviews. Cancer. 4: 423-36. PMID 15170445 DOI: 10.1038/Nrc1369 |
0.395 |
|
| 2004 |
Kerbel RS. Antiangiogenic drugs and current strategies for the treatment of lung cancer. Seminars in Oncology. 31: 54-60. PMID 14981581 DOI: 10.1053/J.Seminoncol.2003.12.015 |
0.455 |
|
| 2004 |
Viloria-Petit AM, Kerbel RS. Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. International Journal of Radiation Oncology, Biology, Physics. 58: 914-26. PMID 14967451 DOI: 10.1016/J.Ijrobp.2003.09.091 |
0.705 |
|
| 2004 |
Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS, Yang BB. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 18: 754-6. PMID 14766798 DOI: 10.1096/Fj.03-0545Fje |
0.738 |
|
| 2004 |
Pak BJ, Lee J, Thai BL, Fuchs SY, Shaked Y, Ronai Z, Kerbel RS, Ben-David Y. Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase. Oncogene. 23: 30-8. PMID 14712208 DOI: 10.1038/Sj.Onc.1207007 |
0.343 |
|
| 2004 |
Bocci G, Danesi R, Del Tacca M, Kerbel RS. Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor. European Journal of Pharmacology. 477: 17-21. PMID 14512093 DOI: 10.1016/J.Ejphar.2003.08.001 |
0.454 |
|
| 2004 |
Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biology & Therapy. 2: S134-9. PMID 14508091 |
0.377 |
|
| 2004 |
Emmenegger U, Morton G, Francia G, Franco M, Man S, Kerbel R. 180 Low-dose metronomic cyclophosphamide induced sustained hypoxia in human tumor xenografts, which can be exploited therapeutically by the combination with the hypoxic cell cytotoxin tirapazamine European Journal of Cancer Supplements. 2: 57. DOI: 10.1016/S1359-6349(04)80188-5 |
0.323 |
|
| 2004 |
Rak J, Kerbel RS. Oncogenes and Tumor Angiogenesis Seminars in Cancer Biology. 14: 171-218. DOI: 10.1007/978-1-59259-313-2_10 |
0.474 |
|
| 2003 |
Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proceedings of the National Academy of Sciences of the United States of America. 100: 12917-22. PMID 14561896 DOI: 10.1073/Pnas.2135406100 |
0.449 |
|
| 2003 |
Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May L, Henkin J, Lobe C, Nagy A, Kerbel RS, Rak J. Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors. The Embo Journal. 22: 4091-102. PMID 12912908 DOI: 10.1093/Emboj/Cdg408 |
0.818 |
|
| 2003 |
Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y, Kerbel RS. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Research. 63: 4342-6. PMID 12907602 |
0.334 |
|
| 2003 |
Gately S, Kerbel R. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Progress in Experimental Tumor Research. 37: 179-92. PMID 12795055 DOI: 10.1159/000071373 |
0.365 |
|
| 2003 |
Master Z, Tran J, Bishnoi A, Chen SH, Ebos JM, Van Slyke P, Kerbel RS, Dumont DJ. Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganization. The Journal of Biological Chemistry. 278: 30170-9. PMID 12777393 DOI: 10.1074/Jbc.M301339200 |
0.548 |
|
| 2003 |
Jones N, Chen SH, Sturk C, Master Z, Tran J, Kerbel RS, Dumont DJ. A unique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function. Molecular and Cellular Biology. 23: 2658-68. PMID 12665569 DOI: 10.1128/Mcb.23.8.2658-2668.2003 |
0.592 |
|
| 2003 |
Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS. High-frequency 3-D color-flow imaging of the microcirculation. Ultrasound in Medicine & Biology. 29: 39-51. PMID 12604116 DOI: 10.1016/s0301-5629(02)00682-8 |
0.62 |
|
| 2003 |
Bocci G, Nicolaou KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Research. 62: 6938-43. PMID 12460910 |
0.367 |
|
| 2003 |
Kerbel RS. Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved Cancer Biology & Therapy. 2: 133-138. DOI: 10.4161/Cbt.213 |
0.447 |
|
| 2002 |
Ebos JM, Tran J, Master Z, Dumont D, Melo JV, Buchdunger E, Kerbel RS. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Molecular Cancer Research : McR. 1: 89-95. PMID 12496355 |
0.656 |
|
| 2002 |
Yu JL, Coomber BL, Kerbel RS. A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation; Research in Biological Diversity. 70: 599-609. PMID 12492501 DOI: 10.1046/J.1432-0436.2002.700913.X |
0.76 |
|
| 2002 |
Goertz DE, Yu JL, Kerbel RS, Burns PN, Foster FS. High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. Cancer Research. 62: 6371-5. PMID 12438217 |
0.683 |
|
| 2002 |
Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nature Reviews. Cancer. 2: 727-39. PMID 12360276 DOI: 10.1038/Nrc905 |
0.368 |
|
| 2002 |
Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Research. 62: 2731-5. PMID 12019144 |
0.325 |
|
| 2002 |
Rak J, Yu JL, Kerbel RS, Coomber BL. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Research. 62: 1931-4. PMID 11929804 |
0.694 |
|
| 2002 |
Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proceedings of the National Academy of Sciences of the United States of America. 99: 4349-54. PMID 11917134 DOI: 10.1073/Pnas.072586399 |
0.81 |
|
| 2002 |
Yu JL, Rak JW, Klement G, Kerbel RS. Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. Cancer Research. 62: 1838-46. PMID 11912163 |
0.72 |
|
| 2002 |
Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science (New York, N.Y.). 295: 1526-8. PMID 11859195 DOI: 10.1126/Science.1068327 |
0.742 |
|
| 2002 |
Kerbel RS. Molecular and physiologic mechanisms of drug resistance in cancer: an overview. Cancer Metastasis Reviews. 20: 1-2. PMID 11831636 DOI: 10.1023/A:1013129128673 |
0.338 |
|
| 2002 |
Kerbel RS, Folkman J. Reply to “Limitations of combination anti-angiogenesis and chemotherapy” Nature Reviews Cancer. 2: 804-804. DOI: 10.1038/Nrc905-C2 |
0.351 |
|
| 2001 |
Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, Rak J. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Reviews. 20: 79-86. PMID 11831651 DOI: 10.1023/A:1013172910858 |
0.819 |
|
| 2001 |
Pak BJ, Chu W, Lu SJ, Kerbel RS, Ben-David Y. Lineage-specific mechanism of drug and radiation resistance in melanoma mediated by tyrosinase-related protein 2. Cancer Metastasis Reviews. 20: 27-32. PMID 11831643 DOI: 10.1023/A:1013175516793 |
0.366 |
|
| 2001 |
Master Z, Jones N, Tran J, Jones J, Kerbel RS, Dumont DJ. Dok-R plays a pivotal role in angiopoietin-1-dependent cell migration through recruitment and activation of Pak. The Embo Journal. 20: 5919-28. PMID 11689432 DOI: 10.1093/Emboj/20.21.5919 |
0.585 |
|
| 2001 |
Mayer B, Klement G, Kaneko M, Man S, Jothy S, Rak J, Kerbel RS. Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas. Gastroenterology. 121: 839-52. PMID 11606498 DOI: 10.1053/Gast.2001.27989 |
0.303 |
|
| 2001 |
Frankel A, Rosen K, Filmus J, Kerbel RS. Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L). Cancer Research. 61: 4837-41. PMID 11406560 |
0.619 |
|
| 2001 |
Rak J, Kerbel RS. Ras regulation of vascular endothelial growth factor and angiogenesis. Methods in Enzymology. 333: 267-83. PMID 11400342 DOI: 10.1016/S0076-6879(01)33062-8 |
0.456 |
|
| 2001 |
Yu JL, Rak JW, Carmeliet P, Nagy A, Kerbel RS, Coomber BL. Heterogeneous vascular dependence of tumor cell populations. The American Journal of Pathology. 158: 1325-34. PMID 11290550 DOI: 10.1016/S0002-9440(10)64083-7 |
0.729 |
|
| 2001 |
Klement G, Mayer B, Hicklin D, Bohlen P, Kerbel R. Metronomic anti-angiogenic combination therapy European Journal of Cancer. 37: S105. DOI: 10.1016/S0959-8049(01)80472-X |
0.309 |
|
| 2000 |
Rak J, Yu JL, Klement G, Kerbel RS. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. The Journal of Investigative Dermatology. Symposium Proceedings / the Society For Investigative Dermatology, Inc. [and] European Society For Dermatological Research. 5: 24-33. PMID 11147671 DOI: 10.1046/j.1087-0024.2000.00012.x |
0.738 |
|
| 2000 |
López-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene. 19: 4611-20. PMID 11030150 DOI: 10.1038/Sj.Onc.1203817 |
0.712 |
|
| 2000 |
Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 6: 3719-28. PMID 10999766 |
0.671 |
|
| 2000 |
Rak J, Mitsuhashi Y, Sheehan C, Krestow JK, Florenes VA, Filmus J, Kerbel RS. Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis. Neoplasia (New York, N.Y.). 1: 23-30. PMID 10935467 DOI: 10.1038/Sj.Neo.7900001 |
0.452 |
|
| 2000 |
Kerbel RS, Viloria-Petit A, Klement G, Rak J. 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. European Journal of Cancer (Oxford, England : 1990). 36: 1248-57. PMID 10882863 DOI: 10.1016/S0959-8049(00)00092-7 |
0.741 |
|
| 2000 |
Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. The Journal of Clinical Investigation. 105: R15-24. PMID 10772661 DOI: 10.1172/Jci8829 |
0.529 |
|
| 2000 |
Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis. 21: 505-15. PMID 10688871 DOI: 10.1093/Carcin/21.3.505 |
0.496 |
|
| 2000 |
Goertz DE, Christopher DA, Yu JL, Kerbel RS, Burns PN, Foster FS. High-frequency color flow imaging of the microcirculation. Ultrasound in Medicine & Biology. 26: 63-71. PMID 10687794 DOI: 10.1016/S0301-5629(99)00101-5 |
0.65 |
|
| 2000 |
Chu W, Pak BJ, Bani MR, Kapoor M, Lu SJ, Tamir A, Kerbel RS, Ben-David Y. Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications. Oncogene. 19: 395-402. PMID 10656687 DOI: 10.1038/Sj.Onc.1203315 |
0.373 |
|
| 1999 |
Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RG, Kerbel RS. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochemical and Biophysical Research Communications. 264: 781-8. PMID 10544009 DOI: 10.1006/Bbrc.1999.1589 |
0.67 |
|
| 1999 |
MacDougall JR, Bani MR, Lin Y, Muschel RJ, Kerbel RS. 'Proteolytic switching': opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. British Journal of Cancer. 80: 504-12. PMID 10408860 DOI: 10.1038/Sj.Bjc.6690385 |
0.339 |
|
| 1999 |
Green SK, Frankel A, Kerbel RS. Adhesion-dependent multicellular drug resistance. Anti-Cancer Drug Design. 14: 153-68. PMID 10405642 |
0.615 |
|
| 1999 |
Krestow JK, Rak J, Filmus J, Kerbel RS. Functional dissociation of anoikis-like cell death and activity of stress activated protein kinase. Biochemical and Biophysical Research Communications. 260: 48-53. PMID 10381342 DOI: 10.1006/Bbrc.1999.0863 |
0.348 |
|
| 1999 |
Kerbel RS. What is the optimal rodent model for anti-tumor drug testing? Cancer Metastasis Reviews. 17: 301-4. PMID 10352884 DOI: 10.1023/A:1006152915959 |
0.442 |
|
| 1999 |
Kerbel RS. Rodent tumor models for anti-cancer drug testing: an overview. Cancer Metastasis Reviews. 17: 261. PMID 10352878 DOI: 10.1023/A:1006167811416 |
0.417 |
|
| 1999 |
Feldkamp MM, Lau N, Rak J, Kerbel RS, Guha A. Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras. International Journal of Cancer. 81: 118-24. PMID 10077162 DOI: 10.1002/(Sici)1097-0215(19990331)81:1<118::Aid-Ijc20>3.0.Co;2-5 |
0.371 |
|
| 1999 |
Flørenes VA, Lu C, Bhattacharya N, Rak J, Sheehan C, Slingerland JM, Kerbel RS. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21(WAF1/CIP1) is lost during progression of human malignant melanoma Oncogene. 18: 1023-1032. PMID 10023678 DOI: 10.1038/Sj.Onc.1202382 |
0.329 |
|
| 1998 |
Bayko L, Rak J, Man S, Bicknell R, Ferrara N, Kerbel RS. The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor. Angiogenesis. 2: 203-17. PMID 14517461 DOI: 10.1023/A:1009275307663 |
0.477 |
|
| 1998 |
Rosen K, Rak J, Jin J, Kerbel RS, Newman MJ, Filmus J. Downregulation of the pro-apoptotic protein Bak is required for the ras-induced transformation of intestinal epithelial cells. Current Biology : Cb. 8: 1331-4. PMID 9843689 DOI: 10.1016/S0960-9822(07)00564-7 |
0.314 |
|
| 1998 |
St Croix B, Man S, Kerbel RS. Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Letters. 131: 35-44. PMID 9839618 DOI: 10.1016/S0304-3835(98)00199-2 |
0.481 |
|
| 1998 |
St. Croix B, Sheehan C, Rak JW, Fłorenes VA, Slingerland JM, Kerbel RS. E-cadherin-dependent growth suppression is mediated by the cyclin- dependent kinase inhibitor p27(KIP1) Journal of Cell Biology. 142: 557-571. PMID 9679152 DOI: 10.1083/Jcb.142.2.557 |
0.347 |
|
| 1998 |
Flørenes VA, Mælandsmo GM, Kerbel RS, Slingerland JM, Nesland JM, Holm R. Protein expression of the cell-cycle inhibitor p27(Kip1) in malignant melanoma: Inverse correlation with disease-free survival American Journal of Pathology. 153: 305-312. PMID 9665492 DOI: 10.1016/S0002-9440(10)65572-1 |
0.347 |
|
| 1998 |
Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, Shirasawa S, Sasazuki T, Kerbel RS. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America. 95: 3609-14. PMID 9520413 DOI: 10.1073/Pnas.95.7.3609 |
0.43 |
|
| 1998 |
St Croix B, Kerbel RS. Cell adhesion and drug resistance in cancer. Current Opinion in Oncology. 9: 549-56. PMID 9370076 DOI: 10.1097/00001622-199711000-00010 |
0.453 |
|
| 1998 |
Kerbel RS, Viloria-Petit A, Okada F, Rak J. Establishing a Link between Oncogenes and Tumor Angiogenesis Molecular Medicine. 4: 286-295. DOI: 10.1007/Bf03401737 |
0.744 |
|
| 1997 |
Kerbel RS. A cancer therapy resistant to resistance. Nature. 390: 335-6. PMID 9389468 DOI: 10.1038/36978 |
0.355 |
|
| 1997 |
Rak J, Kerbel RS. bFGF and tumor angiogenesis--back in the limelight? Nature Medicine. 3: 1083-4. PMID 9334715 DOI: 10.1038/Nm1097-1083 |
0.43 |
|
| 1997 |
Maelandsmo GM, Flørenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O. Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. International Journal of Cancer. 74: 464-9. PMID 9291441 DOI: 10.1002/(Sici)1097-0215(19970822)74:4<464::Aid-Ijc19>3.0.Co;2-9 |
0.32 |
|
| 1997 |
Frankel A, Buckman R, Kerbel RS. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. Cancer Research. 57: 2388-93. PMID 9192815 |
0.652 |
|
| 1997 |
Rak J, Filmus J, Kerbel RS. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. European Journal of Cancer (Oxford, England : 1990). 2438-50. PMID 9059332 DOI: 10.1016/S0959-8049(96)00396-6 |
0.348 |
|
| 1996 |
St. Croix B, Flørenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, Kerbel RS. Impact of the cyclin-dependent kinase inhibitor p27(Kip1) on resistance of tumor cells to anticancer agents Nature Medicine. 2: 1204-1210. PMID 8898746 DOI: 10.1038/Nm1196-1204 |
0.468 |
|
| 1996 |
Rak J, Kerbel RS. Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Cancer Metastasis Reviews. 15: 231-6. PMID 8842495 DOI: 10.1007/Bf00437476 |
0.48 |
|
| 1996 |
Rak J, Filmus J, Finkenzeller G, Grugel S, Marmé D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Reviews. 14: 263-77. PMID 8821090 DOI: 10.1007/Bf00690598 |
0.476 |
|
| 1996 |
Kerbel RS. Significance of tumor-host interactions in cancer growth and metastases. Cancer Metastasis Reviews. 14: 259-62. PMID 8821089 DOI: 10.1007/Bf00690597 |
0.393 |
|
| 1996 |
Croix BS, Rak JW, Kapitain S, Sheehan C, Graham CH, Kerbel RS. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. Journal of the National Cancer Institute. 88: 1285-96. PMID 8797768 DOI: 10.1093/Jnci/88.18.1285 |
0.383 |
|
| 1996 |
Bani M, Rak J, Adachi D, Kerbel R, Ben-David Y. 1 O - Experimental malignant conversion of early stage human melanoma cells: evidence for a dominant phenotype European Journal of Cancer. 32: S1. DOI: 10.1016/0959-8049(96)84756-3 |
0.4 |
|
| 1996 |
Kerbel RS. Commentaries on tumor angiogenesis: an introduction Cancer and Metastasis Reviews. 15: 145-147. DOI: 10.1007/Bf00437465 |
0.433 |
|
| 1995 |
Rak J, Mitsuhashi Y, Erdos V, Huang SN, Filmus J, Kerbel RS. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. The Journal of Cell Biology. 131: 1587-98. PMID 8522614 DOI: 10.1083/Jcb.131.6.1587 |
0.35 |
|
| 1995 |
MacDougall JR, Kerbel RS. Constitutive production of 92-kDa gelatinase B can be suppressed by alterations in cell shape. Experimental Cell Research. 218: 508-15. PMID 7796886 DOI: 10.1006/Excr.1995.1185 |
0.338 |
|
| 1995 |
Rak JW, St Croix BD, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anti-Cancer Drugs. 6: 3-18. PMID 7538829 DOI: 10.1097/00001813-199502000-00001 |
0.507 |
|
| 1994 |
Rak JW, Hegmann EJ, Lu C, Kerbel RS. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. Journal of Cellular Physiology. 159: 245-55. PMID 8163565 DOI: 10.1002/Jcp.1041590208 |
0.489 |
|
| 1994 |
Graham CH, Kobayashi H, Stankiewicz KS, Man S, Kapitain SJ, Kerbel RS. Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents Journal of the National Cancer Institute. 86: 975-982. PMID 8007019 DOI: 10.1093/Jnci/86.13.975 |
0.398 |
|
| 1994 |
Kerbel RS, Kobayashi H, Graham CH. Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes? Journal of Cellular Biochemistry. 56: 37-47. PMID 7806590 DOI: 10.1002/Jcb.240560108 |
0.397 |
|
| 1994 |
Kerbel RS, Rak J, Kobayashi H, Man MS, St. Croix B, Graham CH. Multicellular resistance: A new paradigm to explain aspects of acquired drug resistance of solid tumors Cold Spring Harbor Symposia On Quantitative Biology. 59: 661-672. PMID 7587127 DOI: 10.1101/Sqb.1994.059.01.076 |
0.441 |
|
| 1993 |
Kobayashi H, Man S, Graham CH, Kapitain SJ, Teicher BA, Kerbel RS. Acquired multicellular-mediated resistance to alkylating agents in cancer Proceedings of the National Academy of Sciences of the United States of America. 90: 3294-3298. PMID 8475071 DOI: 10.1073/Pnas.90.8.3294 |
0.418 |
|
| 1993 |
Lu C, Kerbel RS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. The Journal of Cell Biology. 120: 1281-8. PMID 8436594 DOI: 10.1083/Jcb.120.5.1281 |
0.316 |
|
| 1993 |
Rak JW, Kerbel RS. Growth advantage ("clonal dominance") of metastatically competent tumor cell variants expressed under selective two- or three-dimensional tissue culture conditions. In Vitro Cellular & Developmental Biology. Animal. 742-8. PMID 8407718 DOI: 10.1007/Bf02631431 |
0.371 |
|
| 1993 |
Graham CH, Hawley TS, Hawley RG, Macdougall JR, Kerbel RS, Khoo N, Lala PK. Establishment and characterization of first trimester human trophoblast cells with extended lifespan Experimental Cell Research. 206: 204-211. PMID 7684692 DOI: 10.1006/Excr.1993.1139 |
0.339 |
|
| 1993 |
Rak JW, Hegmann EJ, Kerbel RS. The Role of Angiogenesis in Tumor Progression and Metastasis Advances in Molecular and Cell Biology. 7: 205-251. DOI: 10.1016/S1569-2558(08)60241-6 |
0.46 |
|
| 1993 |
Kerbel RS. Growth factors as mediators of malignant tumor progression Cancer and Metastasis Reviews. 12: 215-217. DOI: 10.1007/Bf00665953 |
0.422 |
|
| 1992 |
Kerbel RS, Cornil I, Theodorescu D. Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis. Cancer Metastasis Reviews. 10: 201-15. PMID 1764765 DOI: 10.1007/Bf00050792 |
0.414 |
|
| 1992 |
Wu S, Theodorescu D, Kerbel RS, Willson JKV, Mulder KM, Humphrey LE, Brattain MG. TGF-βi is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector Journal of Cell Biology. 116: 187-196. PMID 1730743 DOI: 10.1083/Jcb.116.1.187 |
0.397 |
|
| 1992 |
Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 13: 31-6. PMID 1722975 DOI: 10.1002/Bies.950130106 |
0.509 |
|
| 1992 |
Lu C, Vickers MF, Kerbel RS. Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 89: 9215-9. PMID 1409627 DOI: 10.1073/Pnas.89.19.9215 |
0.374 |
|
| 1991 |
Theodorescu D, Cornil I, Fernandez BJ, Kerbel RS. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 87: 9047-51. PMID 2247480 DOI: 10.1073/Pnas.87.22.9047 |
0.402 |
|
| 1991 |
Lala PK, Elkashab M, Kerbel RS, Parhar RS. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ. International Immunology. 2: 1149-58. PMID 2090199 DOI: 10.1093/Intimm/2.12.1149 |
0.315 |
|
| 1991 |
Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS. Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proceedings of the National Academy of Sciences of the United States of America. 88: 6028-32. PMID 2068080 DOI: 10.1073/Pnas.88.14.6028 |
0.346 |
|
| 1991 |
Korczak B, Kerbel RS, Dennis J. Constitutive expression and secretion of proteases in non-metastatic SP1 mammary carcinoma cells and its metastatic sublines. International Journal of Cancer. 48: 557-61. PMID 2045200 DOI: 10.1002/Ijc.2910480413 |
0.367 |
|
| 1991 |
Theodorescu D, Cornil I, Sheehan C, Man S, Kerbel RS. Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread. International Journal of Cancer. 47: 118-23. PMID 1985866 DOI: 10.1002/Ijc.2910470121 |
0.451 |
|
| 1991 |
Bell C, Frost P, Kerbel RS. Cytogenetic heterogeneity of genetically marked and metastatically competent "dominant" tumor cell clones. Cancer Genetics and Cytogenetics. 54: 153-61. PMID 1884347 DOI: 10.1016/0165-4608(91)90203-7 |
0.424 |
|
| 1991 |
Graham GM, Guarini L, Moulton TA, Datta S, Ferrone S, Giacomini P, Kerbel RS, Fisher PB. Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons. Cancer Immunology, Immunotherapy : Cii. 32: 382-90. PMID 1672507 DOI: 10.1007/Bf01741333 |
0.334 |
|
| 1991 |
Theodorescu D, Caltabiano M, Greig R, Rieman D, Kerbel RS. Reduction of TGF-beta activity abrogates growth promoting tumor cell-cell interactions in vivo. Journal of Cellular Physiology. 148: 380-90. PMID 1655815 DOI: 10.1002/Jcp.1041480308 |
0.378 |
|
| 1990 |
Sagman U, Mullen JB, Kovacs K, Kerbel R, Ginsberg R, Reubi JC. Identification of somatostatin receptors in human small cell lung carcinoma. Cancer. 66: 2129-33. PMID 2171745 DOI: 10.1002/1097-0142(19901115)66:10<2129::Aid-Cncr2820661015>3.0.Co;2-T |
0.304 |
|
| 1990 |
Cornil I, Kerbel RS, Dennis JW. Tumor cell surface beta 1-4-linked galactose binds to lectin(s) on microvascular endothelial cells and contributes to organ colonization. The Journal of Cell Biology. 111: 773-81. PMID 2116422 DOI: 10.1083/jcb.111.2.773 |
0.312 |
|
| 1990 |
Yagel S, Kerbel R, Lala P, Eldar-Gera T, Dennis JW. Basement membrane invasion by first trimester human trophoblast: requirement for branched complex-type Asn-linked oligosaccharides. Clinical & Experimental Metastasis. 8: 305-17. PMID 2112436 DOI: 10.1007/Bf01810677 |
0.351 |
|
| 1989 |
Korczak B, Robson IB, Lamarche C, Bernstein A, Kerbel RS. Genetic tagging of tumor cells with retrovirus vectors: clonal analysis of tumor growth and metastasis in vivo. Molecular and Cellular Biology. 8: 3143-9. PMID 3211140 DOI: 10.1128/Mcb.8.8.3143 |
0.437 |
|
| 1989 |
Cornil I, Man S, Fernandez B, Kerbel RS. Enhanced tumorigenicity, melanogenesis, and metastases of a human malignant melanoma after subdermal implantation in nude mice. Journal of the National Cancer Institute. 81: 938-44. PMID 2733038 DOI: 10.1093/Jnci/81.12.938 |
0.415 |
|
| 1989 |
Carlow DA, Kerbel RS, Elliott BE. Failure of expression of class I major histocompatibility antigens to alter tumor immunogenicity of a spontaneous murine carcinoma. Journal of the National Cancer Institute. 81: 759-67. PMID 2654405 DOI: 10.1093/Jnci/81.10.759 |
0.32 |
|
| 1989 |
Yagel S, Khokha R, Denhardt DT, Kerbel RS, Parhar RS, Lala PK. Mechanisms of cellular invasiveness: A comparison of amnion invasion in vitro and metastatic behavior in vivo Journal of the National Cancer Institute. 81: 768-775. PMID 2541259 DOI: 10.1093/Jnci/81.10.768 |
0.405 |
|
| 1987 |
Kerbel RS, Waghorne C, Man MS, Elliott B, Breitman ML. Alteration of the tumorigenic and metastatic properties of neoplastic cells is associated with the process of calcium phosphate-mediated DNA transfection. Proceedings of the National Academy of Sciences of the United States of America. 84: 1263-7. PMID 3469668 DOI: 10.1073/Pnas.84.5.1263 |
0.362 |
|
| 1985 |
Carlow DA, Kerbel RS, Feltis JT, Elliott BE. Enhanced Expression of Class I Major Histocompatibility Complex Gene (Dk) Products on Immunogenic Variants of a Spontaneous Murine Carcinoma Journal of the National Cancer Institute. 75: 291-301. DOI: 10.1093/Jnci/75.2.291 |
0.378 |
|
| 1984 |
Nestel FP, Casson PR, Wiltrout RH, Kerbel RS. Alterations in sensitivity to nonspecific cell-mediated lysis associated with tumor progression: characterization of activated macrophage- and natural killer cell-resistant tumor variants. Journal of the National Cancer Institute. 73: 483-91. PMID 6589440 DOI: 10.1093/Jnci/73.2.483 |
0.396 |
|
| 1983 |
Kerbel RS, Lagarde AE, Dennis JW, Donaghue TP. Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor. Molecular and Cellular Biology. 3: 523-38. PMID 6687920 DOI: 10.1128/MCB.3.4.523 |
0.3 |
|
| 1983 |
Lagarde AE, Donaghue TP, Dennis JW, Kerbel RS. Genotypic and Phenotypic Evolution of a Murine Tumor During Its Progression In Vivo Toward Metastasis Journal of the National Cancer Institute. 71: 183-191. DOI: 10.1093/Jnci/71.1.183 |
0.421 |
|
| 1981 |
Roder JC, Beaumont TJ, Kerbel RS, Haliotis T, Kozbor D. Selective natural killer resistance in a clone of YAC lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America. 78: 6396-400. PMID 6947236 DOI: 10.1073/Pnas.78.10.6396 |
0.301 |
|
| 1977 |
Pross HF, Kerbel RS. An assessment of intratumor phagocytic and surface marker-bearing cells in a series of autochthonous and early passaged chemically induced murine sarcomas. Journal of the National Cancer Institute. 57: 1157-67. PMID 1087351 DOI: 10.1093/jnci/57.5.1157 |
0.322 |
|
| 1976 |
Kerbel RS, Pross HF. Fc receptor-bearing cells as a reliable marker for quantitation of host lymphoreticular infiltration of progressively growing solid tumors. International Journal of Cancer. 18: 432-8. PMID 977189 DOI: 10.1002/ijc.2910180406 |
0.303 |
|
| Show low-probability matches. |